Promoter-Driven Molecular Radiotherapy for Prostate Cancer

About Promoter-Driven Molecular Radiotherapy for Prostate Cancer

What this means to patients: Relying upon recent advances in nanomedicine, in particular nanoparticle delivery, this project may provide a new prostate-cancer specific therapy in which a therapeutic transgene is delivered systemically to address both local and metastatic disease.

Synopsis: Dr. Pomper and colleagues propose a new method for treating both primary and metastatic prostate cancer using a nanoparticle harboring a gene promoter that is selectively active within prostate cancer cells. The promoter, known as the progression elevated gene-3 promoter (PEG-Prom), discovered by Dr. Pomper’s co-investigator, Dr. Paul Fisher, will be used to drive production of toxic proteins or proteins capable of concentrating therapeutic radionuclides within transfected cells. Additional studies will attempt to place proteins on the prostate tumor cell surface that can further be leveraged as therapeutic targets.

Martin Pomper, MD, PhD

Johns Hopkins Medicine

Co-investigators:

George Sgouros, PhD (Johns Hopkins Medicine); Paul Fisher, PhD (Virginia Commonwealth University).